There are 2949 resources available
1600P - Low dose pembrolizumab is effective in the treatment of advanced non-small cell lung cancer (NSCLC) with reduced cost
Presenter: Jia Li Low
Session: E-Poster Display
Resources:
Abstract
1601P - Estimated years of potential life lost due to absence of pembrolizumab in SUS
Presenter: Gabriel Lenz
Session: E-Poster Display
Resources:
Abstract
1602P - Estimated years of potential life lost from lack of access to crizotinib: NSCLC ALK+
Presenter: Barbara Cruz
Session: E-Poster Display
Resources:
Abstract
1603P - Can we reduce the acquisition cost of CAR T cell therapies?
Presenter: Michael Schlander
Session: E-Poster Display
Resources:
Abstract
1604P - Aggregated analysis of treatment and survival outcome of all metastatic renal cell carcinoma patients treated from 2014 to 2018 in the Veneto region, Italy
Presenter: Umberto Basso
Session: E-Poster Display
Resources:
Abstract
1605P - Number of untimely deaths prevented with ALK-inhibitors in Brazilian patients with advanced non-small cell lung cancer with ALK driver mutations
Presenter: Rodrigo Pellegrini
Session: E-Poster Display
Resources:
Abstract
1606P - Developing a readiness assessment framework for radioligand therapy
Presenter: Emmanuelle Plucker
Session: E-Poster Display
Resources:
Abstract
1607P - The impact of absolute neutrophil count on clinical trial participation in the United States
Presenter: Bamidele Adesunloye
Session: E-Poster Display
Resources:
Abstract
1608P - Publication rate and characteristics of cancer clinical trials in India
Presenter: Vinay Mathew Thomas
Session: E-Poster Display
Resources:
Abstract
1609P - Cancer care in Croatia, comparison with surrounding countries: Can we do better?
Presenter: Renata Kelemenic-Drazin
Session: E-Poster Display
Resources:
Abstract